Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients Meeting Abstract
| Authors: | Picozzi, V. J.; Pishvaian, M. J.; Mody, K.; Winter, J. M.; Glaspy, J. A.; Larson, T.; Matrana, M. R.; Saikali, K.; Carney, M.; Porter, S.; Yu, P.; Kouchakj, E.; Carrier, E. |
| Abstract Title: | Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 205s |
| Language: | English |
| ACCESSION: | WOS:000442916001593 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4016 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4016 -- Source: Wos |
